RESEARCH · TIRZEPATIDE · EAST ASIAN TRIAL PROGRAMME
Tirzepatide in East Asian Trial Populations: SURPASS J, SURPASS-AP-Combo, SURPASS-CN-MONO, SURMOUNT-CN and SURMOUNT-J
PurixLab’s Tirzepatide 10mg is a research vial of the dual GIP and GLP-1 receptor agonist tirzepatide. Our earlier articles cover a SURPASS and SURMOUNT overview, receptor pharmacology, body composition and liver fat and weight regain after withdrawal. This article looks at a separate part of the evidence base: the randomised trials run entirely in Japan, China and the Asia-Pacific region, and what they add to the global programme. These are findings from published clinical research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Why separate trials in East Asian populations?
A WHO expert consultation concluded that Asian populations have different associations between body-mass index, percentage body fat and health risk than European populations, and that a substantial proportion of Asian people are at high risk of type 2 diabetes and cardiovascular disease at BMIs below 25 kg/m2. The cut-off for observed risk varied from 22 to 25 kg/m2 between populations [1]. The SURPASS J-combo authors gave potential ethnic differences in the pathophysiology of type 2 diabetes as the reason new therapeutics need to be evaluated in Japanese patients [2].
This shows up in the entry criteria. SURMOUNT-CN enrolled Chinese adults with a BMI of at least 28, or at least 24 with a weight-related comorbidity [3]. SURMOUNT-J used the Japanese definition of “obesity disease”: a BMI of at least 27 kg/m2 with two or more obesity-related health disorders, or at least 35 kg/m2 with one [4]. Results from these trials therefore describe populations that would not all qualify for the global SURMOUNT studies.
Type 2 diabetes in Japan: SURPASS J-mono and J-combo
SURPASS J-mono randomised 636 participants at 46 sites in Japan to tirzepatide 5, 10 or 15 mg or dulaglutide 0.75 mg once weekly for 52 weeks. HbA1c fell by 2.4, 2.6 and 2.8 percentage points with tirzepatide versus 1.3 with dulaglutide, and body weight changed by 5.8, 8.5 and 10.7 kg (7.8%, 11.0% and 13.9%) versus 0.5 kg with dulaglutide [5].
Two analyses of this trial looked at physiology. In a substudy of 48 participants given a standardised meal, glucose, insulin, glucagon and C-peptide responses differed from dulaglutide at week 32, and all three tirzepatide groups lost body fat mass by bioelectrical impedance [6]. A prespecified HOMA2 analysis reported fasting insulin reductions of 22.6%, 29.8% and 31.0% relative to dulaglutide and higher model-based insulin sensitivity and beta-cell function indices [7].
SURPASS J-combo was different in design: open-label, with no comparator arm and safety as the primary endpoint. Of 443 participants on a single oral agent, treatment-emergent adverse events occurred in 74%, 74% and 84% of the 5, 10 and 15 mg groups. HbA1c fell from 8.5% to 6.0% in the 5 mg group and from 8.6% to 5.6% in the other two, and body weight fell by 5.1%, 10.1% and 13.2% [2]. A post hoc pooled analysis of East Asian participants across six SURPASS trials (94% from Japan) found similar HbA1c reductions of 2.3% to 3.0% across age and BMI subgroups, but more discontinuations for adverse events in those aged 65 or older [8].
China and the Asia-Pacific region: SURPASS-AP-Combo and SURPASS-CN-MONO
SURPASS-AP-Combo randomised 917 insulin-naive adults on metformin, with or without a sulphonylurea, at 66 hospitals in China, South Korea, Australia and India; 83.2% were in China. Over 40 weeks, HbA1c fell by 2.24, 2.44 and 2.49 percentage points with tirzepatide versus 0.95 with insulin glargine. HbA1c below 7.0% was reached by 75.4%, 86.0% and 84.4% versus 23.7%, and body weight fell by 6.5%, 9.3% and 9.4% while it rose by 2.1% with glargine [9].
SURPASS-CN-MONO compared tirzepatide with placebo in 206 Chinese adults with early type 2 diabetes at 29 centres. HbA1c fell by 2.17, 2.06 and 2.15 percentage points versus 0.13 with placebo at week 40, and body weight by 6.0, 6.1 and 9.7 kg versus 1.0 kg, with no clinically significant or severe hypoglycaemia [10]. Glycaemic effects did not increase from the 5 mg to the 15 mg group in this small trial.
Obesity without diabetes: SURMOUNT-CN and SURMOUNT-J
SURMOUNT-CN randomised 210 Chinese adults (mean age 36.1 years, mean BMI 32.3) to tirzepatide 10 or 15 mg or placebo for 52 weeks. Body weight changed by 13.6% and 17.5% versus 2.3% with placebo, and 87.7% and 85.8% versus 29.3% lost at least 5% [3]. A real-world follow-up of 152 completers found that, 26 weeks after stopping, body weight had risen by 9.1% and 12.3% in the former tirzepatide groups, although net change from trial baseline was still 8.7% and 10.6% below baseline versus 2.5% with placebo [11].
In SURMOUNT-J, 267 participants were randomised; after one site was excluded, 225 were analysed. At week 72, treatment differences versus placebo were 16.1% for 10 mg and 21.1% for 15 mg, and 94% and 96% lost at least 5% versus 20% with placebo [4]. A later analysis reported increases in high-molecular-weight adiponectin of 78.9% and 88.4% and reductions in high-sensitivity CRP of 55.1% and 65.3% (17.7% with placebo). Weight loss correlated with visceral fat reduction (r = 0.722 to 0.837) [12]. Among 102 Japanese participants in the global SURMOUNT-1 trial, mean weight change at week 72 was 12.0%, 22.4% and 22.1% with 5, 10 and 15 mg versus 0.3% with placebo [13].
Are the results different from the global trials?
A 2026 meta-analysis compared SURMOUNT trials with entirely Asian populations (SURMOUNT-CN and SURMOUNT-J, 148 tirzepatide-treated participants) with predominantly non-Asian trials. Percentage weight loss versus placebo was similar (18.16% versus 17.92%, p = 0.94), while absolute weight loss was smaller in the Asian trials (16.72 versus 23.46 kg), largely reflecting lower baseline weight. The authors note that the comparison was underpowered and cannot confirm equivalence [14].
Reading these trials critically
- Comparators differ. Dulaglutide 0.75 mg, insulin glargine, placebo and no comparator at all were used [5,9,10,2], so effect sizes cannot be lined up directly.
- Open-label designs. J-combo and AP-Combo were open-label [2,9], which matters most for adverse-event reporting.
- Estimands. SURMOUNT-J and SURPASS-CN-MONO report headline results under the efficacy estimand [4,10], which describes participants who stay on treatment.
- Small subgroups and sponsorship. Several analyses are post hoc or involve small subgroups [8,13], and the core trials were funded by the manufacturer [5,2,10].
- Duration. Treatment periods range from 40 to 72 weeks [9,4], and none of these trials was designed to assess cardiovascular or kidney outcome events.
What remains open
- Whether lower BMI entry thresholds change the balance of benefit and adverse events in long-term use.
- Whether the plateau between the 10 mg and 15 mg groups seen in some of these trials reflects biology, sample size or tolerability.
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63. PubMed 14726171 · doi:10.1016/S0140-6736(03)15268-3
- Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634-644. PubMed 35914542 · doi:10.1016/S2213-8587(22)00187-5
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024;332(7):551-560. PubMed 38819983 · PMC11337071 · doi:10.1001/jama.2024.9217
- Kadowaki T, Kiyosue A, Shingaki T, et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(5):384-396. PubMed 40031941 · doi:10.1016/S2213-8587(24)00377-2
- Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623-633. PubMed 35914543 · doi:10.1016/S2213-8587(22)00188-7
- Yabe D, Kawamori D, Seino Y, et al. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023;25(2):398-406. PubMed 36184780 · PMC10092154 · doi:10.1111/dom.14882
- Hamamoto Y, Oura T, Hirase T. Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis. Diabetes Ther. 2025;16(4):717-729. PubMed 39951042 · PMC11926299 · doi:10.1007/s13300-025-01704-z
- Kiyosue A, Dunn JP, Cui X, et al. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes Obes Metab. 2023;25(4):1056-1067. PubMed 36545807 · doi:10.1111/dom.14952
- Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500-1510. PubMed 37231074 · doi:10.1038/s41591-023-02344-1
- Yin Y, Ma J, Liu D, et al. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Med. 2026;7(7):101183. PubMed 42296968 · doi:10.1016/j.medj.2026.101183
- Chen C, Ying Z, Tang Q, et al. Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Life Metab. 2025;4(5):loaf024. PubMed 42058132 · PMC13122358 · doi:10.1093/lifemeta/loaf024
- Waki H, Kaneyuki E, Shingaki T, et al. Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study. Endocr Pract. 2026:S1530-891X(26)01148-1. PubMed 42762980 · doi:10.1016/j.eprac.2026.09.006
- Ishigaki Y, Yamada M, Shingaki T, et al. Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial. Obesity (Silver Spring). 2026;34(3):608-621. PubMed 41612966 · PMC12933229 · doi:10.1002/oby.70131
- Kamrul-Hasan ABM, Khalil I, Dutta D, et al. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2026;9(4):e70291. PubMed 42487213 · PMC13392206 · doi:10.1002/edm2.70291